Presentations and Publications

Explore publications related to our glioblastoma research.

Research publications

Review Dr. Sarkaria's published research about glioblastoma, including targeted therapy, patient-derived xenografts, brain metastases, temozolomide (TMZ) chemotherapy resistance, and more.

• Explore publications.

Posters

Our lab has participated in numerous conferences and seminars to present findings about our research on glioblastoma, including novel treatment strategies, gene expression profiles and survival studies. Here, explore select posters related to our research. (PDF files require Adobe Reader.)

• • Preclinical data of a novel DNA-PK inhibitor in combination with radiation therapy shows promise in the treatment of established GBM and lung carcinoma cell lines (PDF)
  • 2024 AACR annual meeting, San Diego, California
• • Defining critical features for successful preclinical use of glioblastoma patient-derived xenografts (PDX) models for therapeutic assessment and clinical trial development (PDF)
  • 2024 AACR annual meeting, San Diego, California
• • The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts (PDF)
  • 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts
• • The utility of pre-clinical trials in glioblastoma patient-derived xenograft (PDXs) models for informing clinical trial development of therapeutic strategies (PDF)
  • 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts
• • Bystander effects of EGFR-targeting 40H3 antibody-drug conjugates in glioblastoma with heterogeneous EGFR expression (PDF)
  • 2023 AACR annual meeting, Orlando, Florida
• • Efficacy and pharmacokinetics of EGFR-targeted antibody-drug conjugates following convection-enhanced delivery in mice with glioblastoma xenografts (PDF)
  • 2022 34th EORTC-NCI-AACR Symposium, Barcelona, Spain
• • AZD1390 radio-sensitizes p53-mutant GBM by disrupting homology-directed DNA repair (PDF)
  • 2022 AACR annual meeting, New Orleans
• • Evaluation of novel therapeutics using the Mayo Clinic GBM Patient-Derived Xenograft (PDX) collection (PDF)
  • 2022 AACR annual meeting, New Orleans
• • Convection enhanced delivery of EGFR-targeting antibody drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient derived xenografts (PDF)
  • 2022 AACR annual meeting, New Orleans
• • WSD-0628, a novel brain penetrant ATM inhibitor, radiosensitizes GBM and melanoma patient derived xenografts (PDF)
  • 2022 AACR annual meeting, New Orleans
• • MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models (PDF)
  • 2019 AACR-EORTC meeting, Boston, Mass.
• • Modeling the clinical paradigm of BAL101553 deployment in patient-derived xenografts (PDX) of glioblastoma (GBM) (PDF)
  • 2019 AACR-EORTC meeting, Boston, Mass.
• • EGFR inhibition in glioblastoma patient-derived xenograft models (PDF)
  • 2019 U54 PSOC site visit
• • The addition of CB-839 to TMZ significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model (PDF)
  • 2019 AACR annual meeting, Atlanta, Ga.
• • Heterogeneity in drug delivery across the blood-brain barrier impacts efficacy of depatuxizumab mafodotin (ABT-414) therapy in glioblastoma (PDF)
  • 2018 AAPS meeting, Washington, D.C.
• • Synthetic luciferin, CycLuc1 improves bioluminescence imaging for intracranial glioblastoma xenografts (PDF)
  • 2018 AACR meeting, Chicago